Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Abbvie Inc (NYSE: ABBV) closed the day trading at $227.7 up 0.02% from the previous closing price of $227.66. In other words, the price has increased by $0.02 from its previous closing price. On the day, 2.66 million shares were traded. ABBV stock price reached its highest trading level at $228.09 during the session, while it also had its lowest trading level at $225.51.
Ratios:
For a better understanding of ABBV, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 70.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.44. For the most recent quarter (mrq), Quick Ratio is recorded 0.60 and its Current Ratio is at 0.72.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on November 13, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $280.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 22 ’25 when Richard A. Gonzalez bought 62,755 shares for $210.84 per share.
Richard A. Gonzalez bought 90,000 shares of ABBV for $18,993,948 on Aug 21 ’25. On Aug 12 ’25, another insider, SALEKI-GERHARDT AZITA, who serves as the EVP, CHIEF OPERATIONS OFFICER of the company, sold 42,370 shares for $198.42 each. As a result, the insider received 8,407,055 and left with 177,292 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 402433474560 and an Enterprise Value of 465654480896. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 171.81, and their Forward P/E ratio for the next fiscal year is 15.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 10.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.75. Its current Enterprise Value per Revenue stands at 7.807 whereas that against EBITDA is 15.775.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.35, which has changed by 0.25268197 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $244.81, while it has fallen to a 52-week low of $164.39. The 50-Day Moving Average of the stock is 0.07%, while the 200-Day Moving Average is calculated to be 11.69%.
Shares Statistics:
Over the past 3-months, ABBV traded about 5.88M shares per day on average, while over the past 10 days, ABBV traded about 6257320 shares per day. A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.09% of the company’s shares, while institutions hold 74.63% stake in the company. Shares short for ABBV as of 1763078400 were 18724102 with a Short Ratio of 3.18, compared to 1760486400 on 18080904. Therefore, it implies a Short% of Shares Outstanding of 18724102 and a Short% of Float of 1.06.
Dividends & Splits
ABBV’s forward annual dividend rate is 6.56, up from 6.56 a year ago. Against a Trailing Annual Dividend Yield of 0.028814899. The stock’s 5-year Average Dividend Yield is 3.75.
Earnings Estimates
. The current market rating for Abbvie Inc (ABBV) reflects the collective analysis of 19.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $3.05, with high estimates of $3.3 and low estimates of $2.84.
Analysts are recommending an EPS of between $10.83 and $10.5 for the fiscal current year, implying an average EPS of $10.64. EPS for the following year is $14.24, with 29.0 analysts recommending between $15.43 and $13.01.
Revenue Estimates
18 analysts predict $16.4B in revenue for . The current quarter. It ranges from a high estimate of $17.01B to a low estimate of $16.23B. As of . The current estimate, Abbvie Inc’s year-ago sales were $15.1BFor the next quarter, 18 analysts are estimating revenue of $14.71B. There is a high estimate of $15.2B for the next quarter, whereas the lowest estimate is $14.45B.
A total of 28 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $61.55B, while the lowest revenue estimate was $60.5B, resulting in an average revenue estimate of $60.93B. In the same quarter a year ago, actual revenue was $56.33BBased on 28 analysts’ estimates, the company’s revenue will be $66.62B in the next fiscal year. The high estimate is $68.67B and the low estimate is $65.31B.
